Sermorelin vs CJC-1295 without DAC

Sermorelin is the first 29 amino acids of human GHRH, unmodified. Mod GRF 1-29 swaps four amino acids to resist enzymatic breakdown, giving it a longer — though still short — active life.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Sermorelin

Synthetic GHRH(1-29) — the shortest fully active fragment of natural growth-hormone-releasing hormone, once a registered paediatric medicine.

BEST STUDIED FOR

GH secretagogues

Read the cited profile →

🧪

	Sermorelin	CJC-1295 without DAC
The key difference	Native GHRH(1-29) sequence	Four substitutions for stability
Class	GH secretagogues	GH secretagogues
Mechanism	Sermorelin is identical to the first 29 amino acids of human GHRH and stimulates GH release from the anterior pituitary through the GHRH receptor, preserving the pituitary’s own pulsatile feedback.	GHRH(1-29)-NH2 is the shortest fully active portion of GHRH.
Status	Formerly approved (Geref) for diagnosis and treatment of idiopathic GH deficiency in children; the branded product was withdrawn commercially.	GHRH(1-29) analogues were studied clinically from the 1980s (GH secretion, paediatric growth). The modified version circulates as a research peptide and has been found in seized doping material.
Reported safety signals	Clinical-era reviews reported it as well tolerated. Recent reviews flag unregulated self-administration of GH-axis peptides as a growing concern.	Older GHRH(1-29) studies reported short-term tolerability; GHRH analogues are prohibited in sport.
A key study	Reviews sermorelin as the shortest synthetic GHRH peptide with full activity, used diagnostically and therapeutically in paediatric GHD. (BioDrugs 1999, PMID 18031173)	Measured GH responses to GHRH(1-29)-NH2 and a D-Ala2-substituted analogue in normal men across a dose range. (Peptides 1985, PMID 2866496)

Sermorelin is the reference GHRH fragment with clinical history; Mod GRF 1-29 is the stabilised research analogue. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Sermorelin] Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — BioDrugs 1999. PMID 18031173
[Sermorelin] PEGylation of growth hormone-releasing hormone (GRF) analogues — Adv Drug Deliv Rev 2003. PMID 14499707
[Sermorelin] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne) 2026. PMID 42395176
[CJC-1295 without DAC] Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men — Peptides 1985. PMID 2866496
[CJC-1295 without DAC] Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies — J Med Chem 1998. PMID 9513600
[CJC-1295 without DAC] Glycine-modified growth hormone secretagogues identified in seized doping material — Drug Test Anal 2019. PMID 30136411

FREQUENTLY ASKED

What is the difference between Sermorelin and CJC-1295 without DAC?

Sermorelin is the first 29 amino acids of human GHRH, unmodified. Mod GRF 1-29 swaps four amino acids to resist enzymatic breakdown, giving it a longer — though still short — active life.

What is the regulatory status of Sermorelin and CJC-1295 without DAC?

Sermorelin: Formerly approved (Geref) for diagnosis and treatment of idiopathic GH deficiency in children; the branded product was withdrawn commercially. CJC-1295 without DAC: GHRH(1-29) analogues were studied clinically from the 1980s (GH secretion, paediatric growth). The modified version circulates as a research peptide and has been found in seized doping material.

What safety signals have been reported?

Sermorelin: Clinical-era reviews reported it as well tolerated. Recent reviews flag unregulated self-administration of GH-axis peptides as a growing concern. CJC-1295 without DAC: Older GHRH(1-29) studies reported short-term tolerability; GHRH analogues are prohibited in sport.

Which studies is this comparison based on?

For Sermorelin: “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency” (PMID 18031173); “PEGylation of growth hormone-releasing hormone (GRF) analogues” (PMID 14499707); “The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration” (PMID 42395176). For CJC-1295 without DAC: “Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men” (PMID 2866496); “Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies” (PMID 9513600); “Glycine-modified growth hormone secretagogues identified in seized doping material” (PMID 30136411).